ProCE Banner Activity

Possibilities for the Future of SERDs Therapy for HR+/HER2- Breast Cancer

Slideset

Download these slides summarizing current and emerging clinical trials on novel treatment approaches with oral SERDs therapy for patients with HR+/HER2- breast cancer, including as adjuvant therapy for early stage disease.

Released: May 30, 2024

Expiration: May 29, 2025

Share

Faculty

Sarah Sammons

Sarah Sammons, MD

Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly